PURPOSE: Outcome misclassification in retrospective epidemiologic analyses has been well-studied, but little is known about such misclassification with respect to sequential statistical analysis during surveillance of medical product-associated risks, a planned capability of the US Food and Drug Administration's Sentinel System. METHODS: Using a vaccine example, we model and simulate sequential database surveillance in an observational data network using a variety of outcome detection algorithms. We consider how these algorithms, as characterized by sensitivity and positive predictive value, impact the length of surveillance and timeliness of safety signal detection. We show investigators/users of these networks how they can perform preparatory study design calculations that consider outcome misclassification in sequential database surveillance. RESULTS: Non-differential outcome misclassification generates longer surveillance times and less timely safety signal detection as compared with the case of no misclassification. Inclusive algorithms characterized by high sensitivity but low positive predictive value outperform more narrow algorithms when detecting rare outcomes. This decision calculus may change considerably if medical chart validation procedures were required. CONCLUSIONS: These findings raise important questions regarding the design of observational data networks used for pharmacovigilance. Specifically, there are tradeoffs involved when choosing to populate such networks with component databases that are large as compared with smaller integrated delivery system databases that can more easily access laboratory or clinical data and perform medical chart validation.
PURPOSE: Outcome misclassification in retrospective epidemiologic analyses has been well-studied, but little is known about such misclassification with respect to sequential statistical analysis during surveillance of medical product-associated risks, a planned capability of the US Food and Drug Administration's Sentinel System. METHODS: Using a vaccine example, we model and simulate sequential database surveillance in an observational data network using a variety of outcome detection algorithms. We consider how these algorithms, as characterized by sensitivity and positive predictive value, impact the length of surveillance and timeliness of safety signal detection. We show investigators/users of these networks how they can perform preparatory study design calculations that consider outcome misclassification in sequential database surveillance. RESULTS: Non-differential outcome misclassification generates longer surveillance times and less timely safety signal detection as compared with the case of no misclassification. Inclusive algorithms characterized by high sensitivity but low positive predictive value outperform more narrow algorithms when detecting rare outcomes. This decision calculus may change considerably if medical chart validation procedures were required. CONCLUSIONS: These findings raise important questions regarding the design of observational data networks used for pharmacovigilance. Specifically, there are tradeoffs involved when choosing to populate such networks with component databases that are large as compared with smaller integrated delivery system databases that can more easily access laboratory or clinical data and perform medical chart validation.
Authors: Richard Platt; Ryan M Carnahan; Jeffrey S Brown; Elizabeth Chrischilles; Lesley H Curtis; Sean Hennessy; Jennifer C Nelson; Judith A Racoosin; Melissa Robb; Sebastian Schneeweiss; Sengwee Toh; Mark G Weiner Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: Jennifer C Nelson; Andrea J Cook; Onchee Yu; Clara Dominguez; Shanshan Zhao; Sharon K Greene; Bruce H Fireman; Steven J Jacobsen; Eric S Weintraub; Lisa A Jackson Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: Lesley H Curtis; Mark G Weiner; Denise M Boudreau; William O Cooper; Gregory W Daniel; Vinit P Nair; Marsha A Raebel; Nicolas U Beaulieu; Robert Rosofsky; Tiffany S Woodworth; Jeffrey S Brown Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: Sharon K Greene; Martin Kulldorff; Ruihua Yin; W Katherine Yih; Tracy A Lieu; Eric S Weintraub; Grace M Lee Journal: Pharmacoepidemiol Drug Saf Date: 2011-06 Impact factor: 2.890
Authors: Grace M Lee; Sharon K Greene; Eric S Weintraub; James Baggs; Martin Kulldorff; Bruce H Fireman; Roger Baxter; Steven J Jacobsen; Stephanie Irving; Matthew F Daley; Ruihua Yin; Allison Naleway; James D Nordin; Lingling Li; Natalie McCarthy; Claudia Vellozzi; Frank Destefano; Tracy A Lieu Journal: Am J Prev Med Date: 2011-08 Impact factor: 5.043
Authors: Sean T O'Leary; Jason M Glanz; David L McClure; Aysha Akhtar; Matthew F Daley; Cynthia Nakasato; Roger Baxter; Robert L Davis; Hector S Izurieta; Tracy A Lieu; Robert Ball Journal: Pediatrics Date: 2012-01-09 Impact factor: 7.124
Authors: Kathleen E Walsh; Sarah L Cutrona; Sarah Foy; Meghan A Baker; Susan Forrow; Azadeh Shoaibi; Pamala A Pawloski; Michelle Conroy; Andrew M Fine; Lise E Nigrovic; Nandini Selvam; Mano S Selvan; William O Cooper; Susan Andrade Journal: Pharmacoepidemiol Drug Saf Date: 2013-09-05 Impact factor: 2.890
Authors: Rosa Gini; Martijn Schuemie; Jeffrey Brown; Patrick Ryan; Edoardo Vacchi; Massimo Coppola; Walter Cazzola; Preciosa Coloma; Roberto Berni; Gayo Diallo; José Luis Oliveira; Paul Avillach; Gianluca Trifirò; Peter Rijnbeek; Mariadonata Bellentani; Johan van Der Lei; Niek Klazinga; Miriam Sturkenboom Journal: EGEMS (Wash DC) Date: 2016-02-08
Authors: Jennifer C Nelson; Robert Wellman; Onchee Yu; Andrea J Cook; Judith C Maro; Rita Ouellet-Hellstrom; Denise Boudreau; James S Floyd; Susan R Heckbert; Simone Pinheiro; Marsha Reichman; Azadeh Shoaibi Journal: EGEMS (Wash DC) Date: 2016-09-06
Authors: Weiling Katherine Yih; Martin Kulldorff; Sukhminder K Sandhu; Lauren Zichittella; Judith C Maro; David V Cole; Robert Jin; Alison Tse Kawai; Meghan A Baker; Chunfu Liu; Cheryl N McMahill-Walraven; Mano S Selvan; Richard Platt; Michael D Nguyen; Grace M Lee Journal: Pharmacoepidemiol Drug Saf Date: 2015-11-17 Impact factor: 2.890